placebo + ceftriaxone

Placebo + ceftriaxone refers to a specific control arm in the INFUSE-Ceftriaxone Phase I clinical trial (NCT01290705) conducted by Baxter Healthcare Corporation. In this study arm, healthy volunteers received a subcutaneous injection of a placebo (0.9% sodium chloride) followed by a subcutaneous dose of ceftriaxone. This regimen served as a comparator to evaluate the safety and pharmacokinetics of subcutaneous ceftriaxone when administered with or without recombinant human hyaluronidase (Hylenex). Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). The study aimed to establish the feasibility and maximum tolerated concentration of subcutaneous ceftriaxone administration.

Other names

SC Placebo and Ceftriaxone